BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06021054 (veligrotug in Chronic Thyroid Eye Disease): BVCT ex-ante prediction vs. reported outcome

On 14 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial partial success for this trial. The 16 Dec 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially maybe sufficient (non-superior to teprotumumab).

Clinical Trial

NCTID
NCT06021054
Acronym
THRIVE-2
Drug Name
veligrotug (VRDN-001)
Drug MoA
anti-IGF1R mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
Best-In-Class
Therapeutic Area
Eye Diseases
Indication
Chronic Thyroid Eye Disease
Human Patients
188
Sponsor
Viridian Therapeutics
Phase
Phase 3

Prediction of , index 1467

Prospective Prediction
Prediction Index
1467
Prediction Date
Commercial Prediction
partial SUCCESS (commercially sufficient clinical benefit non-superior to Tepezza)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
306 days in advance
Readout Data Interpretation
veligrotug achieved 48% placebo-adjusted PRR at week 15; non-superior to teprotumumab (Tepezza) that achieved 65% placebo-adjusted PRR at week 15 (DOI-10.1056/NEJMoa1910434); veligrotug further achieved 31% placebo-adjusted diplopia responder rate at week 15 (p=0.0006); non-superior to teprotumumab that achieved 48% placebo-adjusted diplopia responder rate at week 15 (DOI-10.1056/NEJMoa1910434)
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially maybe sufficient (non-superior to teprotumumab)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-masked, Placebo-controlled Safety, Tolerability, and Efficacy Study of VRDN-001, a Humanized Monoclonal Antibody Directed Against the IGF-1 Receptor, in Participants With Chronic Thyroid Eye Disease (TED)
Phase
Phase 3
Status
Completed
Enrollment
188
Lead sponsor
Viridian Therapeutics, Inc.
Conditions
Thyroid Eye Disease
Interventions
DRUG: Veligrotug; DRUG: Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2023-11-01
Primary completion
2024-11-04
Completion
2025-07-25
Results first posted
2026-08-13
Primary outcomes
  • Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by Exophthalmometer (Baseline to Week 15)

NCT06021054 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials